Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (NYSE:BMY)

Balance Sheet: Assets

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Bristol-Myers Squibb Co., consolidated balance sheet: assets

US$ in millions

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Cash and cash equivalents 12,346  6,911  5,421  4,237  2,385 
Marketable debt securities 3,047  1,973  1,391  2,113  1,885 
Net trade receivables 6,476  4,636  4,347  3,774  2,948 
Alliance, royalties, VAT and other 1,209  1,111  1,262  1,142  1,169 
Receivables 7,685  5,747  5,609  4,916  4,117 
Inventories 4,293  1,195  1,166  1,241  1,221 
Prepaid and refundable income taxes 754  218  691  627  182 
Research and development 410  337  —  —  — 
Assets held-for-sale —  479  —  —  — 
Other 819  300  576  570  625 
Other current assets 1,983  1,334  1,267  1,197  807 
Current assets 29,354  17,160  14,854  13,704  10,415 
Property, plant and equipment 6,252  5,027  5,001  4,980  4,412 
Goodwill 22,488  6,538  6,863  6,875  6,881 
Other intangible assets 63,969  1,091  1,210  1,385  1,419 
Deferred income taxes 510  1,371  1,610  2,996  2,844 
Marketable debt securities 767  1,775  2,480  2,719  4,660 
Equity investments 3,405  674  —  —  — 
Inventories 1,373  429  —  —  — 
Operating lease right-of-use assets 704  —  —  —  — 
Pension and postretirement 456  809  —  —  — 
Restricted cash 390  —  —  —  — 
Other 276  112  1,533  1,048  1,117 
Other non-current assets 6,604  2,024  1,533  1,048  1,117 
Non-current assets 100,590  17,826  18,697  20,003  21,333 
Total assets 129,944  34,986  33,551  33,707  31,748 

Based on: 10-K (filing date: 2020-02-24), 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co.’s current assets increased from 2017 to 2018 and from 2018 to 2019.
Property, plant and equipment Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Bristol-Myers Squibb Co.’s property, plant and equipment increased from 2017 to 2018 and from 2018 to 2019.
Non-current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co.’s non-current assets decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co.’s total assets increased from 2017 to 2018 and from 2018 to 2019.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Bristol-Myers Squibb Co.’s cash and cash equivalents increased from 2017 to 2018 and from 2018 to 2019.
Marketable debt securities Amount of investment in marketable security, classified as current. Bristol-Myers Squibb Co.’s marketable debt securities increased from 2017 to 2018 and from 2018 to 2019.
Net trade receivables Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Bristol-Myers Squibb Co.’s net trade receivables increased from 2017 to 2018 and from 2018 to 2019.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Bristol-Myers Squibb Co.’s inventories increased from 2017 to 2018 and from 2018 to 2019.